<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1142">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332107</url>
  </required_header>
  <id_info>
    <org_study_id>20-30504</org_study_id>
    <nct_id>NCT04332107</nct_id>
  </id_info>
  <brief_title>Azithromycin for COVID-19 Treatment in Outpatients Nationwide</brief_title>
  <acronym>ACTION</acronym>
  <official_title>Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas M. Lietman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This individually randomized telemedicine-based trial aims to evaluate the efficacy of a
      single dose of azithromycin for prevention of progression of COVID-19 in patients with a
      recent positive SARS-CoV-2 test who are not currently hospitalized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of a safe, effective treatment for individuals with mild or moderate COVID-19
      that prevents disease progression and reduces hospitalization would reduce the burden on the
      health system. High dose hydroxychloroquine is being evaluated for SARS-CoV-2 prevention and
      COVID-19 disease treatment, but has a high risk of a number of potentially severe adverse
      events. Recent evidence has indicated that the broad-spectrum macrolide azithromycin may have
      some activity against coronaviruses. Here we propose an individually-randomized,
      placebo-controlled trial to determine the efficacy of a single dose of azithromycin for
      prevention of COVID-19 progression to hospitalization.

      Potential participants will undergo remote eligibility screening with study staff prior to
      enrollment. Upon determination of eligibility and signing electronic informed consent
      documents, participants will be emailed baseline study forms and will be mailed their
      randomized study treatment. At the end of the study (21 days), participants will be emailed a
      final study questionnaire. Note that there will no contact between study staff and
      participants in this trial, minimizing risk of infection spread.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>All-cause hospitalization or emergency room stay of &gt;24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>3 days</time_frame>
    <description>Viral load by self-collected nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>3 days</time_frame>
    <description>Viral load by self-collected saliva swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 days</time_frame>
    <description>Proportion of participants experiencing adverse events, including gastrointestinal side effects and rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - nasal swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - saliva swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected saliva swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - rectal swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected rectal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic macrolide resistance determinants</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of genetic macrolide resistance determinants by self-collected rectal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 symptoms</measure>
    <time_frame>3, 7, 14, 21 days</time_frame>
    <description>Prevalence of cough, fever, myalgia, anosmia, shortness of breath, fatigue, conjunctivitis, and orthostatic symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency room visits</measure>
    <time_frame>14 days</time_frame>
    <description>Number of emergency room visits &lt;24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of household members with COVID-19 (confirmed or symptomatic)</measure>
    <time_frame>14 days</time_frame>
    <description>Number of household members with confirmed or symptomatic COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>21 days</time_frame>
    <description>Deaths within the study will be attempted to be matched with the US National Death Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2271</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2g of oral azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Participants will be shipped a single 1.2 g dose of oral azithromycin</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Participants will be shipped a dose of matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a positive SARS-CoV-2 test and test results received within the previous
             seven days

          -  Not currently hospitalized

          -  Willing and able to receive study drug by mail

          -  Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via
             email or over the phone

          -  No known allergy or other contraindication to macrolides

          -  Age 18 years or older at the time of enrollment

          -  No known history of prolongation of the QT interval (eg. History of torsades de
             pointes, congenital long QT syndrome, bradyarrhthmia)

          -  No recent use of hydroxychloroquine within the past 7 days for participants &gt;55 years
             of age

          -  Not currently taking nelfinavir or warfarin (Coumadin)

          -  Provision of informed consent

          -  Not currently pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Oldenburg, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thuy Doan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica M Brogdon, MPH</last_name>
    <phone>(415) 514-1582</phone>
    <email>ACTIONTrial@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Cook, MPH</last_name>
    <email>ACTIONTrial@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica M Brogdon, MPH</last_name>
      <phone>415-514-1582</phone>
      <email>ACTIONTrial@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

